MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. Academic Article uri icon

Overview

abstract

  • Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III). Four of these patients achieved a partial response, and two achieved a minor response. An additional seven patients had evidence of disease stabilization. The median survival period from initiation of therapy for responders was 13.5 months as compared to 7.6 months for those with stable disease and 3.2 months for nonresponders (p = 0.001). Myelosuppression was the primary toxicity. Prolongation of survival was demonstrated in responding patients who had failed prior chemotherapy. The MIFA III regimen is active, well tolerated, and warrants further investigation in previously untreated patients.

publication date

  • October 1, 1984

Research

keywords

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Pancreatic Neoplasms

Identity

Scopus Document Identifier

  • 0021740262

Digital Object Identifier (DOI)

  • 10.1097/00000421-198410000-00027

PubMed ID

  • 6391145

Additional Document Info

volume

  • 7

issue

  • 5